Lyon, January 25, 2022
Edelris announced today that they have entered into a new agreement for the discovery of innovative and selective ligands on biological targets of interest for Bayer, focusing on addressing new modes of action for disease control in pilot projects.
« Bayer has been a long-standing client of Edelris and we are happy to have the possibility to make the difference with Bayer again! » stated Jean-Yves Ortholand, CEO at Edelris « We will have the opportunity to demonstrate that our technologies can help a leading and global crop protection organization finding meaningful active compounds of next generation. Our team is eager to continue our relationship with this collaboration! »
Edelris will activate EDEN (Edelris Discovery ENgine), combining its dedicated AS-MS (Affinity Selection-Mass Spectrometry) screening technologies and expertise based upon with its proprietary compound library of 2M lead-like members originating from Edelris’ Keymical Space™.
The financial terms are not disclosed.
More news
About Edelris
Our DNA
Edelris has continuously been bringing creative solutions to clients and partners from drug discovery organizations for the past 17 years, with a clear focus on Hit generation and Hit-to-Lead optimization. Edelris has pioneered the value of 3D, natural productlike compound collections for HTS and FBLD (Keymical Collections™ and Fragments), and offers successful medicinal chemistry and synthesis of explorative chemical libraries, encoded and non-encoded. Further to this, Edelris differentiates itself with EDEN (Edelris Discovery ENgine) based upon a 2 million proprietary compound collection (Keymical Space™) and AS-MS technologies.
More info at www.edelris.com and LinkedIn.